DK1455839T3 - Heterobifunktioneller poly(ethylenglycol)-derivater og fremgangsmåder til fremstilling heraf - Google Patents

Heterobifunktioneller poly(ethylenglycol)-derivater og fremgangsmåder til fremstilling heraf

Info

Publication number
DK1455839T3
DK1455839T3 DK99951885.5T DK99951885T DK1455839T3 DK 1455839 T3 DK1455839 T3 DK 1455839T3 DK 99951885 T DK99951885 T DK 99951885T DK 1455839 T3 DK1455839 T3 DK 1455839T3
Authority
DK
Denmark
Prior art keywords
heterobifunctional
poly
derivatives
processes
preparation
Prior art date
Application number
DK99951885.5T
Other languages
Danish (da)
English (en)
Inventor
Michael David Bentley
J Milton Harris
Antoni Kozlowski
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Application granted granted Critical
Publication of DK1455839T3 publication Critical patent/DK1455839T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK99951885.5T 1999-10-08 1999-10-08 Heterobifunktioneller poly(ethylenglycol)-derivater og fremgangsmåder til fremstilling heraf DK1455839T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/023536 WO2001026692A1 (en) 1999-10-08 1999-10-08 Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation

Publications (1)

Publication Number Publication Date
DK1455839T3 true DK1455839T3 (da) 2013-05-06

Family

ID=22273776

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99951885.5T DK1455839T3 (da) 1999-10-08 1999-10-08 Heterobifunktioneller poly(ethylenglycol)-derivater og fremgangsmåder til fremstilling heraf

Country Status (17)

Country Link
EP (1) EP1455839B1 (enExample)
JP (1) JP4344110B2 (enExample)
KR (1) KR100499655B1 (enExample)
CN (1) CN1284603C (enExample)
AU (1) AU781336B2 (enExample)
BR (1) BR9917517A (enExample)
CA (1) CA2386762C (enExample)
CY (1) CY1114128T1 (enExample)
DK (1) DK1455839T3 (enExample)
ES (1) ES2404685T3 (enExample)
HU (1) HU228491B1 (enExample)
IL (2) IL148890A0 (enExample)
MX (1) MXPA02003540A (enExample)
NO (1) NO331781B1 (enExample)
NZ (1) NZ518143A (enExample)
PT (1) PT1455839E (enExample)
WO (1) WO2001026692A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
US7550512B2 (en) 2001-11-28 2009-06-23 Keio University Medical polymers and uses thereof
JP3493608B2 (ja) * 2001-11-28 2004-02-03 学校法人慶應義塾 医用高分子及びその用途
GB0209539D0 (en) * 2002-04-26 2002-06-05 Avecia Ltd Monomer Polymer and process
CN100337689C (zh) 2002-07-24 2007-09-19 弗·哈夫曼-拉罗切有限公司 聚亚烷基二醇酸加合物
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
AU2002353814A1 (en) * 2002-10-15 2004-05-04 Baxter Healthcare S.A. Process for the preparation of polyethylene glycol bis amine
US8034900B2 (en) 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
WO2004060967A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
US9040664B2 (en) 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
US20050214250A1 (en) * 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
EP1868652A2 (en) 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
DE602006005686D1 (de) * 2005-08-26 2009-04-23 Novo Nordisk As Verfahren zur modifizierung eines makromolekularen systems
JP5021649B2 (ja) * 2005-08-26 2012-09-12 ノヴォ ノルディスク アクティーゼルスカブ 高分子システムを変性する方法
LT2049148T (lt) 2006-07-06 2016-11-25 Daewoong Co., Ltd. Žmogaus augimo hormono skysta stabili kompozicija
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
BR112012002709A2 (pt) 2009-08-05 2019-04-30 Pieris Ag formulações de liberação controlada de muteínas de lipocalina
WO2011050938A1 (de) 2009-10-26 2011-05-05 Genovoxx Gmbh Konjugate von nukleotiden und methoden zu deren anwendung
AU2012278944B2 (en) 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2014078733A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
CN103044677A (zh) * 2012-12-28 2013-04-17 上海景宇生物科技有限公司 一种异端基遥爪聚乙二醇及其制备方法
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
CN104774161B (zh) * 2014-01-13 2017-08-25 成都福瑞康生物科技有限公司 多肽、蛋白质peg修饰剂合成方法
WO2017062700A1 (en) * 2015-10-07 2017-04-13 Elementis Specialties, Inc. Wetting and anti-foaming agent
WO2017083306A1 (en) 2015-11-09 2017-05-18 R.P. Scherer Technologies, Llc Anti-cd22 antibody-maytansine conjugates and methods of use thereof
KR102247701B1 (ko) * 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
WO2017180998A2 (en) 2016-04-15 2017-10-19 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
CN109923179A (zh) 2016-12-12 2019-06-21 贝克顿·迪金森公司 水溶性聚合物染料
WO2019133399A1 (en) 2017-12-26 2019-07-04 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
CN112384573A (zh) 2018-03-30 2021-02-19 贝克顿·迪金森公司 含侧基发色团的水溶性聚合染料
EP3813867A1 (en) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Treatment of lymmphatic metastases
JP7342757B2 (ja) * 2019-03-29 2023-09-12 日油株式会社 ヘテロ型単分散ポリエチレングリコール誘導体の製造方法
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
CN113583230A (zh) * 2021-06-30 2021-11-02 苏州欣影生物医药技术有限公司 一种peg双胺选择性反应制备异双官能团的方法
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
US20250383357A1 (en) 2022-07-01 2025-12-18 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
CN115959992A (zh) * 2022-12-13 2023-04-14 武汉翱飞科技有限公司 一种单分子量聚乙二醇单乙酸的合成方法
WO2024196805A1 (en) 2023-03-17 2024-09-26 Beckman Coulter, Inc. Benzothienopyrrole cyanine dyes
CN121866309A (zh) 2023-09-21 2026-04-14 贝克曼库尔特有限公司 用于流式细胞术的二氢菲(dhp)桥接染料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220339C (en) * 1995-05-10 2009-10-13 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates having a spacer comprising polyalkylene glycol and peptide
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
ES2211033T3 (es) * 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
CA2323048C (en) * 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups

Also Published As

Publication number Publication date
BR9917517A (pt) 2002-07-30
NZ518143A (en) 2004-04-30
IL148890A0 (en) 2002-09-12
KR100499655B1 (ko) 2005-07-07
JP4344110B2 (ja) 2009-10-14
AU6423099A (en) 2001-04-23
HUP0203149A2 (en) 2002-12-28
KR20020040841A (ko) 2002-05-30
EP1455839A1 (en) 2004-09-15
IL148890A (en) 2007-09-20
CN1284603C (zh) 2006-11-15
NO331781B1 (no) 2012-03-26
ES2404685T3 (es) 2013-05-28
JP2003511422A (ja) 2003-03-25
PT1455839E (pt) 2013-04-24
NO20021555D0 (no) 2002-04-02
AU781336B2 (en) 2005-05-19
CA2386762A1 (en) 2001-04-19
WO2001026692A1 (en) 2001-04-19
NO20021555L (no) 2002-06-04
CN1374875A (zh) 2002-10-16
CA2386762C (en) 2009-06-16
CY1114128T1 (el) 2016-07-27
EP1455839B1 (en) 2013-01-23
HU228491B1 (en) 2013-03-28
MXPA02003540A (es) 2003-09-12

Similar Documents

Publication Publication Date Title
NO20021555L (no) Heterobifunksjonale poly(etylenglykol)derivater og fremgangsmåter for fremstilling av disse
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
NO2010019I1 (no) 6-per-deoksy-6-per-(2-karboksyl)tio-y-cyklodextrin
NO20022086D0 (no) Antidiabetisk formulering og fremgangsmåte
DK0985697T3 (da) Oxiranderivater og fremgangsmåde til fremstilling deraf
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
IS6264A (is) Arýlmetýl-karbónýlamínó-þíósól afleiður og notkunþeirra sem miðla gegn æxlum
DE60028849D1 (de) Sterilisationsmethode
NO992339D0 (no) Farmas°ytiske formuleringer
NO995386D0 (no) Polybuten-1-(ko)polymerer og fremgangsmÕte for fremstilling av slike
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
PT1181397E (pt) Electrocatalisador de rodio e metodo de preparacao
ID29089A (id) Sediaan farmasi moksifloksasin
DE60017514D1 (de) Laserbehandlungsgerät
NO20002584D0 (no) Brønnreferanseapparat og fremgangsmÕte
NO20022250L (no) Polymerisasjonskatalysator og fremgangsmåte
DE60122160D1 (de) Antennenstruktur und zugehöriges verfahren
DE60033056D1 (de) Wafer fördersystem
DE60013073D1 (de) Aufblasventil
NO20030759L (no) 10-aryl-11-HBENZO(b)fluorenderivater og analoger for medisinsk anvendelse
DE50014156D1 (de) Rastverbindung
ID30032A (id) Formulasi farmasi
ATE250092T1 (de) Polyolformulierung
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20010682D0 (no) Fosforylerte polymerer og konjugater derav